Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients
Lídia Blanco-Silvente, Xavier Castells, Marc Sáez, et al.
The International Journal of Neuropsychopharmacology (2017) Vol. 20, Iss. 7, pp. 519-528
Open Access | Times Cited: 121

Showing 1-25 of 121 citing articles:

Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
Thaiane Coelho dos Santos, Thaís Mota Gomes, Bruno Pinto, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 318
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease
Andrea Haake, Kevin T. Nguyen, Lauren G. Friedman, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 2, pp. 147-157
Closed Access | Times Cited: 140
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Tien-Wei Yu, Hsien‐Yuan Lane, Chieh‐Hsin Lin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8208-8208
Open Access | Times Cited: 127
Small molecules as therapeutic drugs for Alzheimer's disease
Darryll Oliver, P. Hemachandra Reddy
Molecular and Cellular Neuroscience (2019) Vol. 96, pp. 47-62
Open Access | Times Cited: 127
An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine
Rita Khoury, Jayashree Rajamanickam, George T. Grossberg
Therapeutic Advances in Drug Safety (2018) Vol. 9, Iss. 3, pp. 171-178
Open Access | Times Cited: 126
Effects of Music Therapy on Patients with Dementia—A Systematic Review
Hei Long Lam, Wai Tak Victor Li, Ismail Laher, et al.
Geriatrics (2020) Vol. 5, Iss. 4, pp. 62-62
Open Access | Times Cited: 121
Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity
Kevin Mullane, Michael Williams
Current Protocols in Pharmacology (2019) Vol. 84, Iss. 1
Closed Access | Times Cited: 111
The quest for synergy between physical exercise and cognitive stimulation via exergaming in people with dementia: a randomized controlled trial
Esther G.A. Karssemeijer, Justine A. Aaronson, Willem Bossers, et al.
Alzheimer s Research & Therapy (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 108
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning
Md. Tanvir Kabir, Md. Sahab Uddin, Mst. Marium Begum, et al.
Current Pharmaceutical Design (2019) Vol. 25, Iss. 33, pp. 3519-3535
Closed Access | Times Cited: 106
The efficacy and safety of memantine for the treatment of Alzheimer’s disease
Shinji Matsunaga, Taro Kishi, Ikuo Nomura, et al.
Expert Opinion on Drug Safety (2018) Vol. 17, Iss. 10, pp. 1053-1061
Closed Access | Times Cited: 101
Alzheimer’s disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality
Kevin Mullane, Michael Williams
Biochemical Pharmacology (2018) Vol. 158, pp. 359-375
Closed Access | Times Cited: 94
Structure–activity relationship investigation of coumarin–chalcone hybrids with diverse side-chains as acetylcholinesterase and butyrylcholinesterase inhibitors
Lu Kang, Xiao-Hui Gao, Haoran Liu, et al.
Molecular Diversity (2018) Vol. 22, Iss. 4, pp. 893-906
Open Access | Times Cited: 87
Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy
Ashwani Arya, Rubal Chahal, Rekha Rao, et al.
Biomolecules (2021) Vol. 11, Iss. 3, pp. 350-350
Open Access | Times Cited: 84
Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease
Anton Meden, Damijan Knez, Marko Jukič, et al.
Chemical Communications (2019) Vol. 55, Iss. 26, pp. 3765-3768
Closed Access | Times Cited: 79
Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
Marta Pérez, Natalia Burgos‐Alonso, Marı́a Torrecilla, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1689-1689
Open Access | Times Cited: 61
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities
Damijan Knez, Nicolas Coquelle, Anja Pišlar, et al.
European Journal of Medicinal Chemistry (2018) Vol. 156, pp. 598-617
Closed Access | Times Cited: 82
Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials
M. Seibert, Viktoria Mühlbauer, Jill Holbrook, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 41
Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews
Reza Majidazar, Erfan Rezazadeh-Gavgani, Saeed Sadigh‐Eteghad, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 10, pp. 1567-1587
Closed Access | Times Cited: 36
Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis
Michael David, Martina Del Giovane, Kathy Liu, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 10, pp. 1080-1090
Open Access | Times Cited: 35
Effectiveness of lifestyle medicine on cognitive functions in mild cognitive impairments and dementia: A systematic review on randomized controlled trials
Zihan Ding, Pui-Ying Leung, Tsz‐lok Lee, et al.
Ageing Research Reviews (2023) Vol. 86, pp. 101886-101886
Closed Access | Times Cited: 21
Neuroprotective potentials of Lead phytochemicals against Alzheimer's disease with focus on oxidative stress-mediated signaling pathways: Pharmacokinetic challenges, target specificity, clinical trials and future perspectives
Muhammad Ayaz, Osama F. Mosa, Asif Nawaz, et al.
Phytomedicine (2023) Vol. 124, pp. 155272-155272
Closed Access | Times Cited: 20
Cognitive behavior, art, and music therapies intervention for treating the depression of children: A randomized control trial
Ethan Yi Cao, Lu Naixin, Timothy Onosahwo Iyendo, et al.
Psychiatry Research (2024) Vol. 333, pp. 115716-115716
Closed Access | Times Cited: 7
Panax notoginseng saponins prevent dementia and oxidative stress in brains of SAMP8 mice by enhancing mitophagy
Yingying Yang, Wenya Chen, Zhenmei Lin, et al.
BMC Complementary Medicine and Therapies (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Rita Khoury, Kush Patel, Jake Gold, et al.
Drugs & Aging (2017) Vol. 34, Iss. 11, pp. 811-820
Closed Access | Times Cited: 57
An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease
Amanda Calhoun, Christian King, Rita Khoury, et al.
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 15, pp. 1711-1717
Closed Access | Times Cited: 56
Page 1 - Next Page

Scroll to top